

REFERENCES

- Ahn, E., & Kang, H. (2018). Introduction to systematic review and meta-analysis. *Korean Journal of Anesthesiology*, 71(2), 103. <https://doi.org/10.4097/KJAE.2018.71.2.103>
- Alladi, C., Mohan, A., Shewade, D., Rajkumar, R., Adithan, S., & Subramanian, K. (2017). Risperidone-induced adverse drug reactions and role of DRD2 (-141 C Ins/Del) and 5HTR2C (-759 C>T) genetic polymorphisms in patients with schizophrenia. *Journal of Pharmacology and Pharmacotherapeutics*, 8(1), 28–32. https://doi.org/10.4103/jpp.JPP_197_16
- Almoguera, B., Riveiro-Alvarez, R., Lopez-Castroman, J., Dorado, P., Vaquero-Lorenzo, C., Fernandez-Piqueras, J., ... Ayuso, C. (2013). Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population. *Pharmacogenomics Journal*, 13(2), 197–204. <https://doi.org/10.1038/tpj.2011.57>
- Bloechliger, M., Rüegg, S., Jick, S. S., Meier, C. R., & Bodmer, M. (2015). Antipsychotic Drug Use and the Risk of Seizures: Follow-up Study with a Nested Case-Control Analysis. *CNS Drugs*, 29(7), 591–603. <https://doi.org/10.1007/s40263-015-0262-y>
- Chagnon, Y. C., Bureau, A., Gendron, D., Bouchard, R. H., Mérette, C., Roy, M. A., & Maziade, M. (2007). Possible association of the pro-melanin-concentrating hormone gene with a Greater body mass index as a side effect of the antipsychotic olanzapine. *American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics*, 144(8), 1063–1069. <https://doi.org/10.1002/ajmg.b.30554>
- Charlson, F. J., Ferrari, A. J., Santomauro, D. F., Diminic, S., Stockings, E., Scott, J. G., ... Whiteford, H. A. (2018). Global epidemiology and burden of schizophrenia: Findings from the global burden of disease study 2016. *Schizophrenia Bulletin*, 44(6), 1195–1203. <https://doi.org/10.1093/schbul/sby058>
- Chen, Y., Wang, Y., Fang, X., Zhang, Y., Song, L., & Zhang, C. (2020). Association of the HTR2C-759C/T polymorphism and antipsychotic-induced weight gain: A meta-analysis. *General Psychiatry*, 33(3), 100192. <https://doi.org/10.1136/gpsych-2020-100192>
- Chokhawala, K., & Stevens, L. (2020). Antipsychotic Medications. Retrieved from <https://www.ncbi.nlm.nih.gov/books/NBK519503/>
- Chong, H. Y., Teoh, S. L., Wu, D. B. C., Kotirum, S., Chiou, C. F., & Chaiyakunapruk, N. (2016, February 16). Global economic burden of schizophrenia: A systematic review. *Neuropsychiatric Disease and Treatment*. Dove Medical Press Ltd. <https://doi.org/10.2147/NDT.S96649>
- Crouse, E. L., Alastanos, J. N., Bozyski, K. M., & Toscano, R. A. (2017). Dysphagia with second-generation antipsychotics: A case report and review of the literature. *Mental Health Clinician*, 7(2), 56–64. <https://doi.org/10.9740/mhc.2017.03.056>
- Davis, J., Eyre, H., Jacka, F. N., Dodd, S., Dean, O., McEwen, S., ... Berk, M. (2016, June 1). A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis. *Neuroscience and Biobehavioral Reviews*. Elsevier Ltd. <https://doi.org/10.1016/j.neubiorev.2016.03.017>
- De Leon, J., Armstrong, S. C., & Cozza, K. L. (2005). The dosing of atypical antipsychotics. *Psychosomatics*, 46(3), 262–273. <https://doi.org/10.1176/appi.psy.46.3.262>
- Dong, L., Yan, H., Huang, X., Hu, X., Yang, Y., Ma, C., ... Yue, W. (2015). A2BP1 gene polymorphisms

- association with olanzapine-induced weight gain. *Pharmacological Research*, 99, 155–161.
<https://doi.org/10.1016/j.phrs.2015.06.003> LK -
<http://bb2sz3ek3z.search.serialssolutions.com?sid=EMBASE&issn=10961186&id=doi:10.1016%2Fj.phrs.2015.06.003&atitle=A2BP1+gene+polymorphisms+association+with+olanzapine-induced+weight+gain&stitle=Pharmacol.+Res.&title=Pharmacological+Research&volume=99&issue=&spage=155&epage=161&aust=Dong&aufirst=Licai&aunit=L.&aufull=Dong+L.&coden=PHMRE&isbn=&pages=155-161&date=2015&aunit1=L&aunitm=>
- Eggers, A. E. (2013). A serotonin hypothesis of schizophrenia. *Medical Hypotheses*, 80(6), 791–794.
<https://doi.org/10.1016/j.mehy.2013.03.013>
- Eichler, E. E. (2019). Genetic Variation, Comparative Genomics, and the Diagnosis of Disease. *The New England Journal of Medicine*, 381(1), 64. <https://doi.org/10.1056/NEJMRA1809315>
- Elm, E. von, & Egger, M. (2004). The scandal of poor epidemiological research. *BMJ*, 329(7471), 868–869.
<https://doi.org/10.1136/BMJ.329.7471.868>
- Faden, J., & Citrome, L. (2019). Resistance is not futile: treatment-refractory schizophrenia—overview, evaluation and treatment. *Expert Opinion on Pharmacotherapy*, 20(1), 11–24.
<https://doi.org/10.1080/14656566.2018.1543409>
- Gopalakrishnan, S., & Ganeshkumar, P. (2013). Systematic Reviews and Meta-analysis: Understanding the Best Evidence in Primary Healthcare. *Journal of Family Medicine and Primary Care*, 2(1), 9.
<https://doi.org/10.4103/2249-4863.109934>
- Haddad, P. M., & Correll, C. U. (2018). The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. *Therapeutic Advances in Psychopharmacology*, 8(11), 303–318.
<https://doi.org/10.1177/2045125318781475>
- Hany, M., Rehman, B., Azhar, Y., & Chapman, J. (2020a). Schizophrenia. Retrieved from
<https://www.ncbi.nlm.nih.gov/books/NBK539864/>
- Hany, M., Rehman, B., Azhar, Y., & Chapman, J. (2020b). *Schizophrenia. StatPearls*. StatPearls Publishing. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/30969686>
- He, H., Liu, Q., Li, N., Guo, L., Gao, F., Bai, L., ... Lyu, J. (2019). Trends in the incidence and DALYs of schizophrenia at the global, regional and national levels: Results from the Global Burden of Disease Study 2017. *Epidemiology and Psychiatric Sciences*, 29.
<https://doi.org/10.1017/S2045796019000891>
- Herken, H., Erdal, M., Aydin, N., Sengul, C., Karadag, F., Barlas, O., & Akin, F. (2009). The association of olanzapine-induced weight gain with peroxisome proliferator-activated receptor- γ 2 Pro12Ala polymorphism in patients with schizophrenia. *DNA and Cell Biology*, 28(10), 515–519.
<https://doi.org/10.1089/dna.2009.0893>
- HH, Z., & ZQ, L. (2000). Ethnic differences in drug metabolism. *Clinical Chemistry and Laboratory Medicine*, 38(9), 899–903. <https://doi.org/10.1515/CCLM.2000.131>
- Hong, C. J., Lin, C. H., Yu Younger, W. Y., Yang, K. H., & Tsai, S. J. (2001). Genetic variants of the serotonin system and weight change during clozapine treatment. *Pharmacogenetics*, 11(3), 265–268.
<https://doi.org/10.1097/00008571-200104000-00010>
- Hu, X., Zhang, J., Jin, C., Mi, W., Wang, F., Ma, W., ... Yue, W. (2013). Association study of NRXN3

- polymorphisms with schizophrenia and risperidone-induced bodyweight gain in Chinese Han population. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, 43, 197–202. <https://doi.org/10.1016/j.pnpbp.2012.12.007> LK - <http://bb2sz3ek3z.search.serialssolutions.com?sid=EMBASE&issn=02785846&id=doi:10.1016%2Fj.pnpbp.2012.12.007&atitle=Association+study+of+NRXN3+polymorphisms+with+schizophrenia+and+risperidone-induced+bodyweight+gain+in+Chinese+Han+population&stitle=Prog.+Neuro-Psychopharmacol.+Biol.+Psychiatry&title=Progress+in+Neuro-Psychopharmacology+and+Biological+Psychiatry&volume=43&issue=&spage=197&epage=202&aulast=Hu&aufirst=Xiaofeng&aunit=X.&aufull=Hu+X.&coden=PNPPD&isbn>
- Ito, T., Yamamoto, K., Ohsawa, F., Otsuka, I., Hishimoto, A., Sora, I., ... Yano, I. (2018). Association of CYP2D6 polymorphisms and extrapyramidal symptoms in schizophrenia patients receiving risperidone: a retrospective study. *Journal of Pharmaceutical Health Care and Sciences*, 4(1). <https://doi.org/10.1186/s40780-018-0126-y>
- J, M., & D, W. (2012). Cytochrome P450 variations in different ethnic populations. *Expert Opinion on Drug Metabolism & Toxicology*, 8(3), 371–382. <https://doi.org/10.1517/17425255.2012.657626>
- Jassim, G., Fernø, J., Theisen, F. M., Haberhausen, M., Christoforou, A., Håvik, B., ... Steen, V. M. (2011). Association study of energy homeostasis genes and antipsychotic-induced weight gain in patients with schizophrenia. *Pharmacopsychiatry*, 44(1), 15–20. <https://doi.org/10.1055/s-0030-1263174> LK - <http://bb2sz3ek3z.search.serialssolutions.com?sid=EMBASE&issn=01763679&id=doi:10.1055%2Fs-0030-1263174&atitle=Association+study+of+energy+homeostasis+genes+and+antipsychotic-induced+weight+gain+in+patients+with+schizophrenia&stitle=Pharmacopsychiatry&title=Pharmacopsychiatry&volume=44&issue=1&spage=15&epage=20&aulast=Jassim&aufirst=G.&aunit=G.&aufull=Jassim+G.&coden=PHRME&isbn=&pages=15-20&date=2011&aunit1=G&aunitm=>
- Jentsch, J. D., & Roth, R. H. (1999, March). The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. *Neuropsychopharmacology*. *Neuropsychopharmacology*. [https://doi.org/10.1016/S0893-133X\(98\)00060-8](https://doi.org/10.1016/S0893-133X(98)00060-8)
- Kang, S. G., Lee, H. J., Park, Y. M., Choi, J. E., Han, C., Kim, Y. K., ... Kim, L. (2008). Possible association between the -2548A/G polymorphism of the leptin gene and olanzapine-induced weight gain. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, 32(1), 160–163. <https://doi.org/10.1016/j.pnpbp.2007.08.002>
- Kang, S. H., Lee, J. H., Chang, A. K., Joo, Y. H., Kim, C. Y., & Kim, S. Y. (2011). Genetic polymorphisms in the HTR2C and peroxisome proliferator-activated receptors are not associated with metabolic syndrome in patients with schizophrenia taking clozapine. *Psychiatry Investigation*, 8(3), 262–268. <https://doi.org/10.4306/pi.2011.8.3.262>
- Kohlrausch, F. B., Severino-Gama, C., Lobato, M. I., Belmonte-de-Abreu, P., Carracedo, Á., & Hutz, M. H. (2013). The CYP1A2 -163C>A polymorphism is associated with clozapine-induced generalized tonic-clonic seizures in Brazilian schizophrenia patients. *Psychiatry Research*, 209(2), 242–245. <https://doi.org/10.1016/j.psychres.2013.02.030>
- Koskinen, S., Kampman, O., Solismaa, A., Lyytikäinen, L.-P., Seppälä, N., Viikki, M., ... Leinonen, E. (2016). INSIG2 polymorphism and weight gain, dyslipidemia and serum adiponectin in Finnish patients with schizophrenia treated with clozapine. *Pharmacogenomics*, 17(18), 1987–1997. <https://doi.org/10.2217/pgs-2016-0117> LK -

<http://bb2sz3ek3z.search.serialssolutions.com?sid=EMBASE&issn=17448042&id=doi:10.2217%2Fp gs-2016-0117&atitle=INSIG2+polymorphism+and+weight+gain%2C+dyslipidemia+and+serum+adiponectin+in+Finnish+patients+with+schizophrenia+treated+with+clozapine&stitle=Pharmacogenomics&title=Pharmacogenomics&volume=17&issue=18&spage=1987&epage=1997&aualast=Koskinen&aufirst=Suvi&auinit=S.&aufull=Koskinen+S.&coden=PARMF&isbn=&pages=1987-1997&date=2016&auinit1=S&auinitm=>

- Lafuente, A., Bernardo, M., Mas, S., Crescenti, A., Aparici, M., Gassó, P., ... Parellada, E. (2007). Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics. *Schizophrenia Research, 90*(1–3), 115–122. <https://doi.org/10.1016/j.schres.2006.09.031>
- Liao, J., Wang, N., Ma, M., Lu, T., Yan, H., & Yue, W. (2020). C677T Polymorphism in the MTHFR Gene Is Associated With Risperidone-Induced Weight Gain in Schizophrenia. *Frontiers in Psychiatry, 11*. <https://doi.org/10.3389/fpsy.2020.00617>
- Little, J., Higgins, J. P. T., Ioannidis, J. P. A., Moher, D., Gagnon, F., von Elm, E., ... Birkett, N. (2009). Strengthening the reporting of genetic association studies (STREGA): An extension of the STROBE Statement. *Human Genetics, 125*(2), 131–151.
- Lopez, D. (2018). Pharmacogenetics: An Important Part of Drug Development with A Focus on Its Application. *International Journal of Biomedical Investigation, 1*(2), 1–16. <https://doi.org/10.31531/2581-4745.1000111>
- Lu, A. Y. H. (1998). Drug-Metabolism Research Challenges in the New Millennium. *Drug Metabolism and Disposition, 26*(12).
- Lucca, J., Madhan, R., Parthasarathi, G., & Ram, D. (2014). Identification and management of adverse effects of antipsychotics in a tertiary care teaching hospital. *Journal of Research in Pharmacy Practice, 3*(2), 46. <https://doi.org/10.4103/2279-042X.137063>
- M, C. (2007). The Cochrane Collaboration and systematic reviews. *The British Journal of Surgery, 94*(4), 391–392. <https://doi.org/10.1002/BJS.5812>
- McDonald, C., & Murphy, K. C. (2003, March). The new genetics of schizophrenia. *Psychiatric Clinics of North America, 27*(2), 257–270. [https://doi.org/10.1016/S0193-953X\(02\)00030-8](https://doi.org/10.1016/S0193-953X(02)00030-8)
- Miller, D. D., Ellingrod, V. L., Holman, T. L., Buckley, P. F., & Arndt, S. (2005). Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism. *American Journal of Medical Genetics - Neuropsychiatric Genetics, 133 B*(1), 97–100. <https://doi.org/10.1002/ajmg.b.30115>
- Nucifora, F. C., Mihaljevic, M., Lee, B. J., & Sawa, A. (2017). Clozapine as a Model for Antipsychotic Development. *Neurotherapeutics, 14*(3), 750–761. <https://doi.org/10.1007/s13311-017-0552-9>
- Osanlou, O., Pirmohamed, M., & Daly, A. K. (2018). Pharmacogenetics of Adverse Drug Reactions. In *Advances in Pharmacology* (Vol. 83, pp. 155–190). Academic Press Inc. <https://doi.org/10.1016/bs.apha.2018.03.002>
- Park, Y. M., Cho, J. H., Kang, S. G., Choi, J. E., Lee, S. H., Kim, L., & Lee, H. J. (2008). Lack of association between the -759C/T polymorphism of the 5-HT₂C receptor gene and olanzapine-induced weight gain among Korean schizophrenic patients. *Journal of Clinical Pharmacy and Therapeutics, 33*(1), 55–60. <https://doi.org/10.1111/j.1365-2710.2008.00872.x>

- Park, Young Min, Choi, J. E., Kang, S. G., Koo, S. H., Kim, L., Geum, D., & Lee, H. J. (2011). Cannabinoid type 1 receptor gene polymorphisms are not associated with olanzapine-induced weight gain. *Human Psychopharmacology*, *26*(4–5), 332–337. <https://doi.org/10.1002/hup.1210>
- Park, Young Min, Chung, Y. C., Lee, S. H., Lee, K. J., Kim, H., Byun, Y. C., ... Lee, H. J. (2006). Weight gain associated with the α 2a-adrenergic receptor -1291 C/G polymorphism and olanzapine treatment. *American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics*, *141*(4), 394–397. <https://doi.org/10.1002/ajmg.b.30311>
- Patel, K. R., Cherian, J., Gohil, K., & Atkinson, D. (2014, September 1). Schizophrenia: Overview and treatment options. *P and T*. Medi Media USA Inc. Retrieved from [/pmc/articles/PMC4159061/](http://pmc/articles/PMC4159061/)
- Read, J., & Williams, J. (2019). Positive and Negative Effects of Antipsychotic Medication: An International Online Survey of 832 Recipients. *Current Drug Safety*, *14*(3), 173–181. <https://doi.org/10.2174/1574886314666190301152734>
- Rietschel, M., Naber, D., Fimmers, R., Möller, H. J., Propping, P., & Nöthen, M. M. (1997). Efficacy and side-effects of clozapine not associated with variation in the 5-HT₂(C) receptor. *NeuroReport*, *8*(8), 1999–2003. <https://doi.org/10.1097/00001756-199705260-00040>
- Ross, E., Barnett, R., Tudhope, R., & Vasudev, K. (2018). Can we improve physical health monitoring for patients taking antipsychotics on a mental health inpatient unit? *Journal of Clinical Psychopharmacology*, *38*(5), 447–453. <https://doi.org/10.1097/JCP.0000000000000931>
- Siever, L. J., & Davis, K. L. (2004, March). The Pathophysiology of Schizophrenia Disorders: Perspectives from the Spectrum. *American Journal of Psychiatry*. *Am J Psychiatry*. <https://doi.org/10.1176/appi.ajp.161.3.398>
- Siskind, D., McCartney, L., Goldschlager, R., & Kisely, S. (2016). Clozapine v . first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis . *British Journal of Psychiatry*, *209*(5), 385–392. <https://doi.org/10.1192/bjp.bp.115.177261>
- Song, X., Pang, L., Feng, Y., Fan, X., Li, X., Zhang, W., ... Lv, L. (2014). Fat-mass and obesity-associated gene polymorphisms and weight gain after risperidone treatment in first episode schizophrenia. *Behavioral and Brain Functions*, *10*(1). <https://doi.org/10.1186/1744-9081-10-35>
- Srivastava, V., Deshpande, S. N., Nimgaonkar, V. L., Lerer, B., & Thelma, B. K. (2008). Genetic correlates of olanzapine-induced weight gain in schizophrenia subjects from north India: Role of metabolic pathway genes. *Pharmacogenomics*, *9*(8), 1055–1068. <https://doi.org/10.2217/14622416.9.8.1055>
- Stroup, T. S., & Gray, N. (2018, October 1). Management of common adverse effects of antipsychotic medications. *World Psychiatry*. Blackwell Publishing Ltd. <https://doi.org/10.1002/wps.20567>
- Suzuki, Y., Tsuneyama, N., Fukui, N., Sugai, T., Watanabe, J., Ono, S., ... Someya, T. (2014). Effect of risperidone metabolism and P-glycoprotein gene polymorphism on QT interval in patients with schizophrenia. *The Pharmacogenomics Journal*, *14*(5), 452–456. <https://doi.org/10.1038/tpj.2014.6>
- T P, A. (2009). Pharmacogenomics: The Right Drug to the Right Person. *Journal of Clinical Medicine Research*, *1*(4), 191. <https://doi.org/10.4021/jocmr2009.08.1255>
- Theisen, F. M., Hinney, A., Brömel, T., Heinzl-Gutenbrunner, M., Martin, M., Krieg, J. C., ... Hebebrand, J. (2004). Lack of association between the -759C/T polymorphism of the 5-HT_{2C} receptor gene and

- clozapine-induced weight gain among German schizophrenic individuals. *Psychiatric Genetics*, 14(3), 139–142. <https://doi.org/10.1097/00041444-200409000-00003>
- Tsai, S. J., Yu, Y. W. Y., Lin, C. H., Wang, Y. C., Chen, J. Y., & Hong, C. J. (2004). Association study of adrenergic β 3 receptor (Trp64Arg) and G-protein β 3 subunit gene (C825T) polymorphisms and weight change during clozapine treatment. *Neuropsychobiology*, 50(1), 37–40. <https://doi.org/10.1159/000077939>
- Turner, R. T., Dube, M., Branscum, A. J., Wong, C. P., Olson, D. A., Zhong, X., ... Iwaniec, U. T. (2015). Hypothalamic leptin gene therapy reduces body weight without accelerating age-related bone loss. *Journal of Endocrinology*, 227(3), 129–141. <https://doi.org/10.1530/JOE-15-0280>
- Vasudev, K., Choi, Y.-H., Norman, R., Kim, R. B., & Schwarz, U. I. (2017). Genetic Determinants of Clozapine-Induced Metabolic Side Effects. *Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie*, 62(2), 138–149. <https://doi.org/10.1177/0706743716670128>
- Viiikki, M., Kampman, O., Seppälä, N., Mononen, N., Lehtimäki, T., & Leinonen, E. (2014). CYP1A2 polymorphism -1545C > T (rs2470890) is associated with increased side effects to clozapine. *BMC Psychiatry*, 14(1). <https://doi.org/10.1186/1471-244X-14-50>
- Vita, A., & Barlati, S. (2018, May 1). Recovery from schizophrenia: Is it possible? *Current Opinion in Psychiatry*. Lippincott Williams and Wilkins. <https://doi.org/10.1097/YCO.0000000000000407>
- Volpi, S., Heaton, C., Mack, K., Hamilton, J. B., Lannan, R., Wolfgang, C. D., ... Lavedan, C. (2009). Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. *Molecular Psychiatry*, 14(11), 1024–1031. <https://doi.org/10.1038/mp.2008.52>
- Wang, F., Mi, W., Ma, W., Ma, C., Yang, Y., Zhang, H., ... Yue, W. (2015). A pharmacogenomic study revealed an association between SLC6A4 and risperidone-induced weight gain in Chinese Han population. *Pharmacogenomics*, 16(17), 1943–1949. <https://doi.org/10.2217/pgs.15.133>
- Wang, Y.-C., Bai, Y.-M., Chen, J.-Y., Lin, C.-C., Lai, I.-C., & Liou, Y.-J. (2010). Genetic association between TNF-alpha -308 G>A polymorphism and longitudinal weight change during clozapine treatment. *Human Psychopharmacology*, 25(4), 303–309. <https://doi.org/10.1002/hup.1122>
- Wang, Y. C., Bai, Y. M., Chen, J. Y., Lin, C. C., Lai, I. C., & Liou, Y. J. (2005). C825T polymorphism in the human G protein beta3 subunit gene is associated with long-term clozapine treatment-induced body weight change in the Chinese population. *Pharmacogenetics and Genomics*, 15(10), 743–748. <https://doi.org/10.1097/01.fpc.0000175600.26893.fa>
- Yang, L., Chen, J., Liu, D., Yu, S., Cong, E., Li, Y., ... Xu, Y. (2015). Association between SREBF2 gene polymorphisms and metabolic syndrome in clozapine-treated patients with schizophrenia. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 56, 136–141. <https://doi.org/10.1016/j.pnpbp.2014.08.015>
- Yasui-Furukori, N., Saito, M., Tsuchimine, S., Nakagami, T., Sato, Y., Sugawara, N., & Kaneko, S. (2008). Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 32(6), 1491–1495. <https://doi.org/10.1016/j.pnpbp.2008.05.006>
- Zhang, C., Zhang, Y., Cai, J., Chen, M., & Song, L. (2017). Complement 3 and metabolic syndrome induced by clozapine: A cross-sectional study and retrospective cohort analysis. *Pharmacogenomics*

Journal, 17(1), 92–97. <https://doi.org/10.1038/tpj.2015.68>

- Zhang, X. Y., Tan, Y. L., Zhou, D. F., Haile, C. N., Cao, L. Y., Xu, Q., ... Kosten, T. R. (2007). Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population. *Journal of Clinical Psychopharmacology*, 27(3), 246–251. <https://doi.org/10.1097/jcp.0b013e3180582412>
- Zhang, Y., Chen, M., Chen, J., Wu, Z., Yu, S., Fang, Y., & Zhang, C. (2014). Metabolic syndrome in patients taking clozapine: Prevalence and influence of catechol-O-methyltransferase genotype. *Psychopharmacology*, 231(10), 2211–2218. <https://doi.org/10.1007/s00213-013-3410-4>
- Zivković, M., Mihaljević-Peles, A., Bozina, N., Sagud, M., Nikolac-Perkovic, M., Vuksan-Cusa, B., & Muck-Seler, D. (2013). The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol. *Journal of Clinical Psychopharmacology*, 33(5), 593–599. <https://doi.org/10.1097/JCP.0b013e31829abec9> LK -
<http://bb2sz3ek3z.search.serialssolutions.com?sid=EMBASE&issn=02710749&id=doi:10.1097%2FJCP.0b013e31829abec9&atitle=The+association+study+of+polymorphisms+in+DAT%2C+DRD2%2C+and+COMT+genes+and+acute+extrapyramidal+adverse+effects+in+male+schizophrenic+patients+reated+with+haloperidol&stitle=J.+Clin.+Psychopharmacol.&title=Journal+of+Clinical+Psychopharmacology&volume=33&issue=5&spage=593&epage=599&aualast=Zivkovi%C4%87&aufirst=Maja&aunit=M.&aufull=Zivkovi%C4%87>